mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Inclusion criteria

• signed informed consent form;
• confirmed as colorectal cancer by pathology, and the stage is IIIB /IIIC according to the NCCN guidelines;
• patients with primary colorectal cancer;
• radical resection of colon cancer (CME) or radical resection of rectal cancer (TME) has done;
• 3~4 weeks after radical resection ;
• patients did not receive any radiotherapy and chemotherapy before operation

Exclusion criteria

• emergency operation for colorectal cancer patients;
• the situation after operation can not tolerance for systemic adjuvant chemotherapy (hemoglobin <95g/L, white blood cell <3 * 109/L, granulocyte <1.5 * 109/L and platelet <75 * 109/L, bilirubin>2.5N, alanine aminotransferase >2.5N, alkaline phosphatase >2.5N, urea nitrogen >2.5N, creatinine >2.5N, proteinuria, hematuria, temperature of >38 degree);
• serious diseases such as cardiac insufficiency, respiratory insufficiency, liver and kidney dysfunction, serious blood diseases;
• patients participated in other clinical trials at the same time;
• pregnant or perinatal women;
• combined with other malignant tumors;
• a history of neuropsychiatric disorders;
• patients have used anti angiogenesis targeted drugs (such as bevacizumab, cetuximab);
• patients had a history of severe trauma within 4 weeks before admission;
• allergic to chemotherapy drugs or apatinib;
• active bleeding, ulcers, intestinal perforation, intestinal obstruction, hypertension